Search filters

Filters
Clear All

Phase

  • 1
  • 2
  • 8
  • 11
  • 10
  • 11

Found 11 Chimeric antigen receptor trials

A listing of Chimeric antigen receptor medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years and younger
All genders
Phase 1
See protocol section 2 See protocol section 2 See protocol section 2
 A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2)
18-99 years
All genders
Interventional
The purpose of this study is to see if JNJ-68284528 is safe and useful for treating patients with relapsed or refractory multiple myeloma.
99 years and younger
All genders
We are doing this study to see if CAR T-cell therapy (bb2121) and maintenance therapy with the drug lenalidomide can help delay multiple myeloma from coming back.
99 years and younger
All genders
Phase 1
This study tests the effects of an investigational product, CT-0508, and to see how safe CT-0508 is for patients with advanced cancer. One purpose of this study is to see if CT-0508 cells can be made and then safely given back to patients with HER2-positive cancers. A second purpose is …
99 years and younger
All genders
Please refer to Protocol Section 2 (Study Hypothesis/Objectives). Please refer to Protocol Section 3.5 (Primary Endpoints). Please refer to Protocol Section 3.6 (Secondary Endpoints).
99 years and younger
All genders
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy for the treatment of relapsed or refractory large B-cell lymphoma.
99 years and younger
All genders
Please refer to Protocol Section 2 (Objectives and Endpoints. Please refer to Protocol Section 2 (Objectives and Endpoints. Please refer to Protocol Section 2 (Objectives and Endpoints.
99 years and younger
All genders
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
99 years and younger
All genders
Please see the Protocol, Section 2 (Objectives and Endpoints) Please see the Protocol, Section 2 (Objectives and Endpoints) Please see the Protocol, Section 2 (Objectives and Endpoints)
99 years and younger
All genders
Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands).
1 - 10 of 11